NDAORALTABLET, EXTENDED RELEASE
Approved
Mar 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CLARINEX D 24 HOUR (desloratadine; pseudoephedrine sulfate) by Merck & Co. is long-acting tricyclic histamine antagonist with selective h 1 -receptor histamine antagonist activity. First approved in 2005.
Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Clarinex D 24 Hour is a combination oral extended-release tablet containing desloratadine, a long-acting tricyclic histamine H1-receptor antagonist, plus pseudoephedrine sulfate for nasal decongestant support. It is indicated for relief of allergic rhinitis symptoms and is designed to provide 24-hour symptom control without significant CNS penetration. The formulation combines antihistamine efficacy with decongestant action for comprehensive allergy symptom management.
LOE Approaching
Product is approaching loss of exclusivity, signaling potential team restructuring and shift from growth to defensive lifecycle management strategies.
Mechanism of Action
long-acting tricyclic histamine antagonist with selective H 1 -receptor histamine antagonist activity. Receptor binding data indicates that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 -receptor. Desloratadine inhibited…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Clarinex D 24 Hour offers limited new growth opportunities given its LOE-approaching status and zero linked job postings, making it a consolidation or exit asset for most career trajectories. However, roles supporting this product may transition to defensive market share protection, generic competition mitigation, or launch preparation for next-generation formulations.
Brand Manager
Worked on CLARINEX D 24 HOUR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.